Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of syringic acid-(4-hydroxy-3,5-dimethoxybenzoic acid) in preparation of drugs for treating acute inflammation

A technology of dimethoxybenzoic acid and acute inflammation is applied in the field of inhibiting proteasome compounds to achieve the effects of reducing inflammatory response, increasing survival rate and aggravating inflammatory response

Inactive Publication Date: 2014-04-30
NANTONG REPAIR AIR CHEM BIOENG
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite this, no well-developed proteasome compound inhibitors are available for the treatment of sepsis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of syringic acid-(4-hydroxy-3,5-dimethoxybenzoic acid) in preparation of drugs for treating acute inflammation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] In vitro target enzyme of polypeptide inhibitor: IC50 value of tumor necrosis factor releasing enzyme (both purchased from sigma company).

[0016] The activity of TNF-releasing enzyme was detected by cleaving the fluorescent substrate Mca-Pro-Leu-Ala-Gln-Ala-Val-Dpa-Arg-Ser-Ser-Ser-Arg-NH (excitation wavelength = 320 nm, Emission wavelength = 405 nm). Reactions were performed in 100 μl reactions at 37°C. At the beginning of the reaction, 4 μl of syringic acid-(4-hydroxy-3,5-dimethoxybenzoic acid) stock solution (1 ng / μl) was added to the reaction system, and the final concentration of the substrate was 10 μM. The measured IC50 value was 4.01 μmol.

Embodiment 2

[0018] Examination of in vivo activity of compound (syringic acid-(4-hydroxy-3,5-dimethoxybenzoic acid)) using endotoxic shock model

[0019] Before establishing the endotoxic shock model, we first determined that the LD50 of LPS (E. coli 0111: B4, purchased from sigma company) mice was 50 μg per mouse, and we used 100 μg per mouse in the experiment , In this way, the mice in the control group can all die. A positive control experiment was done with Regasepin2. The mice in the control group were injected with 100 μg of LPS, while the mice in the Regasepin2 experimental group were injected with 0.7 mg of the compound 5 minutes after LPS injection. By making a Kaplan-Meier survival curve, it was found that Regasepin2 can effectively protect mice injected with 100 μg and improve the survival rate. After the endotoxin shock model was successfully established in mice, the in vivo activity of the compound was tested using the model. The mice in the control group (12) were injecte...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of drugs, and particularly relates to a compound capable of inhibiting proteasomes and relieving damage of an acute inflammatory reaction to bodies. The compound has the molecular structure of syringic acid-(4-hydroxy-3,5-dimethoxybenzoic acid), can increase the survival rate of endotoxic shock mice in in-vivo tests, and has potential new drug development value.

Description

technical field [0001] The invention relates to proteasome-inhibiting compounds and applications thereof, in particular to compounds capable of inhibiting proteasomes and alleviating damage to the body caused by acute inflammatory reactions. Background technique [0002] Sepsis has always been a serious medical problem. Early sepsis without timely and effective treatment can progress to severe sepsis and septic shock, with mortality rates of 20% to 30% and 40% to 70%, respectively. The medical community has been studying effective treatments, such as early symptomatic treatment, activated protein C, and corticosteroid treatment. In recent years, with the deepening of medical research, great progress has been made in the understanding and treatment of sepsis. Among them, the proteasome plays an important role in endotoxic shock. [0003] Proteasomes are ubiquitous in eukaryotes and archaea. In eukaryotes, proteasomes are located in the nucleus and cytoplasm. The main func...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/192A61P29/00
Inventor 姚炎华朱鹏葛亮刘晓磊奚年英
Owner NANTONG REPAIR AIR CHEM BIOENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com